A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

Passing patient information to the police

Description
In what circumstances should medical professionals pass confidential information to the police?
Url
/HealthProfessionals/Clinical-law-updates/Passing-patient-information-to-the-police.aspx

Colorectal multidisciplinary team - patient information

Description
Following your diagnosis of bowel (colorectal) cancer, you will be cared for by a team of medical experts and health professionals
Url
/Media/UHS-website-2019/Patientinformation/Cancercare/Colorectal-multidisciplinary-team-1152-PIL.pdf

Hannah Schiff

Description
Auto Generated Title Congratulations to Dr Hannah Schiff, who has been awarded an MRC Clinical Research Training Fellowship to investigate novel diagnostics in pulmonary tuberculosis, a disease that kills 1.8 million people a year. Hannah is a registrar in adult respiratory medicine who began her specialist training at Southampton General Hospital in 2013. She qualified in medicine and completed her foundation and core medical training in the Oxford Deanery, having come to medicine as a graduate following an initial degree in Natural Sciences at Cambridge. She had always aimed to harness her science background in combination with her medical knowledge to develop a research interest in pulmonary infection. Hannah has benefitted from clear and supportive mentorship during her time in Southampton, which has allowed her to develop her research proposal whilst progressing through her clinical training. In March 2017 she was appointed as a Respiratory Research Fellow at the NIHR Southampton Biomedical Research Centre, which provided a key stepping stone to obtaining a personal research fellowship. Hannah will use the fellowship funding from October 2017 in a cross disciplinary project at the under the dual supervision of Professor Paul Elkington and Dr Spiros Garbis. She will be investigating two large tuberculosis patient cohorts to identify blood biomarkers of pulmonary tuberculosis. Her work aims to distinguish those with active disease from uninfected patients in a format that will permit the development of a highly sensitive near patient test for population screening. This would enable rapid identification of infectious patients and thus prompt effective treatment to break the cycle of transmission, with consequent individual patient and population benefits worldwide. Find out more about Southampton's tuberculosis research
Url
/ClinicalResearchinSouthampton/For-researchers/Education-and-training/Careerpathways/Inspirational-career-stories/Hannah-Schiff.aspx

Chimeric antigen receptor T-cell (CAR-T) therapy - patient information

Description
This factsheet explains what chimeric antigen receptor T-cell (CAR-T) therapy is and what it involves so you know what to expect.
Url
/Media/UHS-website-2019/Patientinformation/Cancercare/Chimeric-antigen-receptor-T-cell-CAR-T-therapy-3739-PIL.pdf

Prof Christian Ottensmeier, director NIHR CRUK

Description
NIHR CRUK Experimental Cancer Medicine Centre Auto Generated Title An oncology consultant and researcher specialising in melanoma, leukaemia, and cancers of the chest, Christian Ottensmeier is at the forefront of research into cancer vaccines. Email: C.h.ottensmeier@soton.ac.uk Professor Christian Ottensmeier leads the NIHR Southampton Biomedical Research Centre's research into lung cancer. Skin, eye and chest cancers Professor Christian Ottensmeier leads research into new immune-based treatments for solid cancers and leukaemia, which work by directing the body ’ s own defences to attack cancerous cells. As a consultant oncologist Christian ’ s clinical research focuses on melanoma (including rare melanomas of the eye) and cancers of the chest. Academically his interest is in developing and then trialing new immune therapies with patients, with a particular interest in cancer vaccines. Directing clinical trials and linking with industry A core aim for Christian is to enable early access to new therapies for cancer patients. He and his Southampton colleagues do so by linking clinical services, scientists and leading pharmaceutical companies through the work of the Experimental Cancer Medicine Centre and CRUK centre. Christian provides patients with access to a wide range of new treatments through direction of early-stage trials in partnership with leading pharmaceutical companies, which like all his early-stage studies take place in Southampton ’ s clinical research facility . Cancer vaccines This approach helps the body ’ s immune system to recognise and kill cancer cells, giving new options for beating cancer; find out more in our focus on immunotherapies. Christian's group's first DNA vaccine showed promising results in early-stage clinical trials for lymphoma, myeloma and prostate cancer. The team has developed several more vaccines and these are being tested in clinical trials for the treatment of several cancers including leukaemia, head and neck cancer, bowel, breast and lung cancer. Christian and his team are improving the design of DNA vaccines and other cancer vaccines with others senior scientists in Southampton, and how they are given to patients. They are also developing techniques to monitor effects on the body ’ s immune system following treatment, with early trials planned in breast cancer and head and neck cancer. Collaborations and national roles Christian works closely with scientific colleagues in the Southampton CRUK Centre, such as Prof Gareth Thomas, Prof Tim Elliott and Prof Martin Glennie to quickly develop discoveries into trial treatments, in collaboration with clinical researchers at other sites throughout the UK, including Cambridge, Leeds, London and Sheffield. Christian is also a steering committee member in the European Cancer Immunotherapy collaborative (CIMT) and the US based Cancer Immunotherapy Consortium (CIC). These collaborative groups work towards standardisation of tests that measure success and failure of immune therapies in patients. Christian is a member of several research funding committees that evaluate grant applications, including for CRUK. Training and career Christian graduated in M ü nster, Germany and began his specialist training there. After a three year training fellowship in the Dana Farber Cancer Institute in Boston, Massachusetts, he moved to Southampton where he completed his oncology training and also undertook his PhD. He has been a consultant in medical oncology since 2000.
Url
/ClinicalResearchinSouthampton/Our-people/Cancer-research-people/Prof-Christian-Ottensmeier-director-NIHR-CRUK-Experimental-Cancer-Medicine-Centre.aspx

Doctors and nurses to play key role in major city road safety event

Description
Doctors and nurses from Southampton Children's Hospital and the Queen Alexandra Hospital in Portsmouth will take to the streets this weekend in a bid to help drive down the number of accidents on roads across the south.
Url
/AboutTheTrust/Newsandpublications/Latestnews/2017/May-2017/Doctors-and-nurses-to-play-key-role-in-major-city-road-safety-event.aspx

Prof Christian Ottensmeier, research lead for lung cancer

Description
NIHR CRUK Experimental Cancer Medicine Centre Auto Generated Title An oncology consultant and researcher specialising in melanoma, leukaemia, and cancers of the chest, Christian Ottensmeier is at the forefront of research into cancer vaccines. Email: C.h.ottensmeier@soton.ac.uk Professor Christian Ottensmeier is director of the NIHR CRUK Experimental Cancer Medicine Centre and leads the NIHR Southampton Biomedical Research Centre's research into lung cancer. Skin, eye and chest cancers Professor Christian Ottensmeier leads research into new immune-based treatments for solid cancers and leukaemia, which work by directing the body ’ s own defences to attack cancerous cells. As a consultant oncologist Christian ’ s clinical research focuses on melanoma (including rare melanomas of the eye) and cancers of the chest. Academically his interest is in developing and then trialing new immune therapies with patients, with a particular interest in cancer vaccines. Directing clinical trials and linking with industry A core aim for Christian is to enable early access to new therapies for cancer patients. He and his Southampton colleagues do so by linking clinical services, scientists and leading pharmaceutical companies through the work of the Experimental Cancer Medicine Centre and CRUK centre. Christian provides patients with access to a wide range of new treatments through direction of early-stage trials in partnership with leading pharmaceutical companies, which like all his early-stage studies take place in Southampton ’ s clinical research facility . Cancer vaccines This approach helps the body ’ s immune system to recognise and kill cancer cells, giving new options for beating cancer; find out more in our focus on immunotherapies. Christian's group's first DNA vaccine showed promising results in early-stage clinical trials for lymphoma, myeloma and prostate cancer. The team has developed several more vaccines and these are being tested in clinical trials for the treatment of several cancers including leukaemia, head and neck cancer, bowel, breast and lung cancer. Christian and his team are improving the design of DNA vaccines and other cancer vaccines with others senior scientists in Southampton, and how they are given to patients. They are also developing techniques to monitor effects on the body ’ s immune system following treatment, with early trials planned in breast cancer and head and neck cancer. Collaborations and national roles Christian works closely with scientific colleagues in the Southampton CRUK Centre, such as Prof Gareth Thomas, Prof Tim Elliott and Prof Martin Glennie to quickly develop discoveries into trial treatments, in collaboration with clinical researchers at other sites throughout the UK, including Cambridge, Leeds, London and Sheffield. Christian is also a steering committee member in the European Cancer Immunotherapy collaborative (CIMT) and the US based Cancer Immunotherapy Consortium (CIC). These collaborative groups work towards standardisation of tests that measure success and failure of immune therapies in patients. Christian is a member of several research funding committees that evaluate grant applications, including for CRUK. Training and career Christian graduated in M ü nster, Germany and began his specialist training there. After a three year training fellowship in the Dana Farber Cancer Institute in Boston, Massachusetts, he moved to Southampton where he completed his oncology training and also undertook his PhD. He has been a consultant in medical oncology since 2000.
Url
/ClinicalResearchinSouthampton/Our-people/Respiratory-research-people/Prof-Christian-Ottensmeier-research-lead-for-lung-cancer.aspx

Clinical law updates

Description
On these pages I discuss the clinical law and the common law relating to information disclosure.
Url
/HealthProfessionals/Clinical-law-updates/Clinicallawupdates.aspx

UHS launches COVID ZERO campaign to help protect patients and staff

Description
A campaign has been launched to wipe out the transmission of COVID-19 in Southampton's hospitals – and the community is being called on to play a vital part.University Hospital Southampton is now planning to bring back services and healthcare support and is leading from the frontline in ensuring that patients who need treatment can access it safely.
Url
/AboutTheTrust/Newsandpublications/Latestnews/2020/July/UHS-launches-COVID-ZERO-campaign-to-help-protect-patients-and-staff.aspx

ABC: A duty to balance conflicting interests

Description
A court considers whether conflicting interests were fairly balanced.
Url
/HealthProfessionals/Clinical-law-updates/ABC-A-duty-to-balance-conflicting-interests.aspx
1 to 10 of 28
Previous 1 2 3 Next